Please Wait...

Mark W. Tengowski

Translation skills

Main profile

Mark W. Tengowski, DVM, MS, PhD
Mark W. Tengowski, DVM, MS, PhD
Scientific Director, MSK & More Medical Affairs

Dr. Tengowski brings a large breadth of applied medical knowledge, critical thinking ability, and drug development experience from compound nomination through post-marketing investigations to Bioclinica. In the industry since 1999, his imaging experience spans ultrastructural- and light-level microscopic evaluations to non-invasive imaging methods, applying imaging endpoints to nominate and advance compounds, manage safety findings, and achieve regulatory approval. Mark served as a medical advisor to the Business Development team, supporting new requests for clinical trials and consultation while being a scientific expert for projects with an inflammation or musculoskeletal focus (e.g., osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, NAFLD/NASH and cholangitis, Crohn's disease, ulcerative colitis, deep vein thrombosis, women's health [breast volume/density, vaginal dryness, uterine fibroids, and endometrial thickness], medical devices, and orphan diseases [hyperoxaluria, acid sphingomyelinase deficiency, Pompe disease, Gaucher disease, Niemann-Pick disease]). With a veterinary background in inflammation and pharmacology, Mark approaches protocols from a mechanistic point of view – devising an imaging strategy that will achieve the study's objective and end points. In the external environment, Mark has been an invited speaker to the FDA and been the author of draft guidance issuances, given posters and podium presentations at national and international meetings, participated in several disease workshops, and published numerous abstracts, articles, and book chapters. Dr. Tengowski is a graduate of the University of Wisconsin-Madison and is licensed to practice veterinary medicine in WI and NY states, with USDA-accreditation, and a member of the American College of Rheumatology.

Authored Publications

Mark Tengowski, DVM, PhD, Scientific Director, Bioclinica; Thomas Fuerst, PhD, Chief Science Officer, Bioclinica, and Claude B Sirlin, UC San Diego Medical Center and UC San Diego Liver Imaging Group. Magnetic resonance imaging fatty liver changes following surgical, lifestyle or drug treatments in obese, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis subjects. Journal of Imaging Medicine, September 2017.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Thanks everyone who joined us in today's webinar! https://t.co/Wp6D0oLfc3
Bioclinica (5 minutes ago)
Kicking off at 11 EST!! https://t.co/v4hMLK9oAZ
Bioclinica (2 hours ago)
BREAKING: Bioclinica Launches NAFLD/NASH Clinical Trials Practice. Helps sponsors apply medical imaging in trials t… https://t.co/JLTxoevbXU
Bioclinica (5 hours ago)
BREAKING: Bioclinica launches #NAFLD #NASH clinical trials practice, helping sponsors apply medical imaging in tria… https://t.co/eUy34LiSAd
Bioclinica (7 hours ago)
Attending the #NASH Summit next week? If so, drop by @bioclinica's exhibit to learn how medical imaging is being u… https://t.co/TNkl7ce4Sq
Bioclinica (Yesterday)
RT @bioclinica: Sponsors conducting clinical trials in #NAFLD or #NASH are invited to join us in an upcoming webinar exploring the use of n…
Bioclinica (Yesterday)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box